VAERS reports by lot

Novavax COVID-19 lot 5683MF012: VAERS reports

34 VAERS reports list lot 5683MF012 as a Novavax COVID-19 vaccine, received between 2023-10-13 and 2024-10-23. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
34
Reports
3%
Marked serious
0
With a death outcome
9
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
Neurological2525%
Injection-site / Local reaction1919%
General / Systemic (non-local)1212%
Dermatological (non-injection-site)1111%
Musculoskeletal1010%
Gastrointestinal88%
Cardiac / Cardiovascular44%
Allergic / Anaphylactic44%
Respiratory44%
Thrombotic / Hematological11%
Psychiatric / Neuropsychiatric11%

Where reports came from

U.S. state of the reporter, where given (top 12).

California5
Pennsylvania4
New York4
Washington3
Texas2
Colorado2
Rhode Island2
Georgia1
Michigan1
Arizona1
Oregon1
Missouri1

Reports by month received

2023-105
2023-118
2024-018
2024-032
2024-041
2024-053
2024-064
2024-091
2024-102

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.